Table 2.
Serum dilution | BR329 baseline |
BR329 5 weeks |
BR332 baseline |
BR332 5 weeks |
BR332 3 months |
BR334 baseline |
BR334 5 weeks |
BR334 3 months |
---|---|---|---|---|---|---|---|---|
1:5 | 94 ± 10 | 6 ± 1 | 93 ± 5 | 5 ± 2 | 5 ± 2 | 107 ± 26 | 4 ± 2 | 3 ± 0 |
1:10 | 104 ± 6 | 6 ± 1 | 101 ± 4 | 6 ± 2 | 6 ± 2 | 113 ± 16 | 7 ± 5 | 5 ± 1 |
1:100 | 110 ± 13 | 6 ± 2 | 99 ± 10 | 7 ± 1 | 120 ± 6 | 106 ± 14 | 5 ± 2 | 113 ± 15 |
1:1,000 | 107 ± 4 | 118 ± 8 | 105 ± 5 | 18 ± 4 | 95 ± 8 | 102 ± 11 | 48 ± 8 | 98 ± 10 |
1:10,000 | 115 ± 12 | 98 ± 8 | 103 ± 8 | 95 ± 7 | 100 ± 5 | 103 ± 7 | 96 ± 3 | 99 ± 5 |
Numbers reflect the percent eGFP expression in presence of sample (mean ± SD). The percent eGFP expression in the absence of sample is 100 ± 6 (n = 36); results indicating ≥50% inhibition are shown in boldface text.